Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

Inclusion Criteria: Histological documentet cutaneous malognant melanoma Stage IIIa, IIIb, IIIc (AJCC 2002) R0 resection dating back no longer than 56 days Performance status (ECOG o-1) Bone marrow funktion: White cell count > 3000 cells/ul, platletts > 100000 cells/ul, hemoglobin > 10 g/dl Liver and kidney funktion: Serum creatinin < 1.5 times upper limit of normal, AST and ALT < 2.5 times upper limit of normal, Serum bilirubin < 2 times upper limit of normal Written inform consent Exclusion Criteria: Confirmed distant metastasis Choroid or mucosal melanoma Pregnant or lactating women and women of childbearing potential not using a reliable form of contraception Active autoimmun disease patients with history of neuropsychiatric disease requiring hospitalization Severe medical condition such us: Florid hepatitis Severe acute infection Myocardial infarction within the past year,symptomatic angina pectoris Grade III to IV congestive heart failure serious pulmonary disease HIV-positive patients with an AIDS - defining condition treatment in another clinical drug trial within the last 30 days A history of hypersensitivity to interferon alfa History of maignant disease during the past 5 years (except for curatively treated skin carcinoma or in situ carcinoma) Prior high dose interferon alfa therapy.Prior adjuvant low dose or intermediate-dose interferon alfa therapy is allowed